Citizens & Northern Corp Acquires 327 Shares of Johnson & Johnson (NYSE:JNJ)

Citizens & Northern Corp raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 14.7% in the fourth quarter, Holdings Channel reports. The fund owned 2,555 shares of the company’s stock after buying an additional 327 shares during the quarter. Citizens & Northern Corp’s holdings in Johnson & Johnson were worth $370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of JNJ. Knuff & Co LLC raised its stake in shares of Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after acquiring an additional 64 shares in the last quarter. Vertex Planning Partners LLC raised its stake in shares of Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock worth $844,000 after acquiring an additional 65 shares in the last quarter. Freedom Day Solutions LLC increased its stake in shares of Johnson & Johnson by 1.1% in the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock worth $1,016,000 after buying an additional 66 shares during the period. Corepath Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 3.7% in the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock worth $287,000 after buying an additional 70 shares during the period. Finally, Lifestyle Asset Management Inc. increased its stake in shares of Johnson & Johnson by 4.7% in the fourth quarter. Lifestyle Asset Management Inc. now owns 1,560 shares of the company’s stock worth $226,000 after buying an additional 70 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts recently commented on JNJ shares. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus decreased their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $159.62 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock has a market cap of $384.29 billion, a PE ratio of 24.00, a price-to-earnings-growth ratio of 2.49 and a beta of 0.52. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company’s fifty day moving average price is $148.61 and its 200-day moving average price is $155.89.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the business posted $2.29 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.11%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.